4- amino- 1,2,4,5- tetrahydro- 2- benzazepin- 3- one
structure in first source
Also Known As:
4-ATHB cpd
Networked: 1
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
| 1. | Balboni, Gianfranco:
1 article
(01/2009)
|
| 2. | Ballet, Steven:
1 article
(01/2009)
|
| 3. | Feytens, Debby:
1 article
(01/2009)
|
| 4. | Graaf, Chris de:
1 article
(01/2009)
|
| 5. | Lattanzi, Roberta:
1 article
(01/2009)
|
| 6. | Lazarus, Lawrence H:
1 article
(01/2009)
|
| 7. | Marczak, Ewa D:
1 article
(01/2009)
|
| 8. | Negri, Lucia:
1 article
(01/2009)
|
| 9. | Rognan, Didier:
1 article
(01/2009)
|
| 10. | Salvadori, Severo:
1 article
(01/2009)
|
Related Diseases
| 1. | Tics (Tic)
01/15/2009
- " Replacement of the constrained phenylalanine analogue 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) in the opioid Dmt-Tic-Gly-NH-Bn scaffold by the 4-amino-1,2,4,5-tetrahydro-indolo[2,3-c]azepin-3-one (Aia) and 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one (Aba) scaffolds has led to the discovery of novel potent mu-selective agonists (Structures 5 and 12) as well as potent and selective delta-opioid receptor antagonists (Structures 9 and 15). "
|
|
Related Drugs and Biologics